The American Association for Clinical Chemistry (AACC) released guidance on lab testing for acute kidney injury (AKI) patients that proposes new diagnostic thresholds for whether a patient has AKI with creatinine testing.
One of the major recommendations is to propose that clinicians use the 20/20 AACC acute kidney injury criteria to determine whether a patient has an injured kidney using creatinine testing. This was recommended due to recent evidence that has linked the 2012 Kidney Disease Improving Global Outcomes guidelines for creatinine testing with high rates of false positives
Total global sales of reagents, test kits, and related products based on kidney disease biomarkers are expected to reach just over $1 billion in 2027. Improvements in the predictive, detection, and prognostic capabilities and overall sensitivity of tests for acute and chronic kidney disorders will underlie growth. Additionally, an expanding worldwide base of vulnerable increase will increase the need for testing. Risk factors for acute and chronic kidney disorders include elderly age, obesity, diabetes, high blood pressure, and heart disease. This is per Kalorama Information’s report o bio markers: https://kaloramainformation.com/product/world-market-for-biomarkers/